University of California, San Francisco San Francisco United States
The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND expIND phase 0 application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen PSMA that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.